Laurus Labs (BOM:540222) ROCE % : 14.31% (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Laurus Labs's annualized ROCE % for the quarter that ended in Dec. 2024 was 14.31%.

Laurus Labs ROCE % Historical Data

The historical data trend for Laurus Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs ROCE % Chart

Laurus Labs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

18.51

50.69

30.59

25.89

7.77

Laurus Labs Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															6.69	11.12	5.13	5.72	14.31

Laurus Labs ROCE % Calculation

Laurus Labs's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	4081.2	/	( ( (76604 - 24322.6)	+	(83870.3 - 31122.8) )	/ 2 )
	=	4081.2	/	( (52281.4	+	52747.5)	/ 2 )
	=	4081.2	/	52514.45
	=	7.77 %

Laurus Labs's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	7539.2	/	( ( (87292.8 - 34594.6)	+	(0 - 0) )	/ 1 )
	=	7539.2	/	( ( 52698.2	+	0 )	/ 1 )
	=	7539.2	/	52698.2
	=	14.31 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Laurus Labs (BOM:540222) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Laurus Labs ROCE % Related Terms

Thank you for viewing the detailed overview of Laurus Labs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Laurus Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » ROCE %

Traded in Other Exchanges

LAURUSLABS:India

Address

Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034

Website

https://www.lauruslabs.com

Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs Headlines

No Headlines